Drugs / Autologous-derived CD22-targeted CAR-T cells
Autologous-derived CD22-targeted CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03999697 | Dec 2018 → Dec 2020 | MALT lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +2 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous-derived CD22-targeted CAR-T cells | “The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day” NCT03999697 ↗ |
| Modality | Cell therapy | “CD22-targeted chimeric antigen receptor T(CAR-T) cells” NCT03999697 ↗ |
| Route | Other | “by infusion” NCT03999697 ↗ |